Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?
A new long-acting ondansetron product that reduces nausea and vomiting during acute viral gastroenteritis, whatever the type of virus involved and for long periods of time, could change the way emergency physicians respond to gastroenteritis outbreaks, and is underpinning the specialty pharma business strategy of RedHill Biopharma.
You may also be interested in...
Company eyes a slice of market for diarrhea-predominant irritable bowel syndrome, a growing space in recent years with the entry of new products.
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.